arrow
J

Jiřı́ Mayer

Masaryk University
H指数:68
被引数:2.8万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

The adverse prognostic impact of HMGCLL1 gene variants can be abrogated by frontline second-generation tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia

HMGCLL1基因变异的不良预后影响可通过一线二代酪氨酸激酶抑制剂疗法在慢性髓系白血病患者中消除。

Leukemia
IF13.4
2026-03-300
PRE
Chronic myeloid leukaemia: have basophils gone the way of the Dodo bird?

慢性髓系白血病:嗜碱性粒细胞是否已走向灭绝?

Leukemia
IF13.4
2026-03-160
OAAI
Repression of miR-29 via MYC leads to increased CD40 signaling in transformed follicular lymphoma

通过MYC抑制miR-29会导致转化性滤泡性淋巴瘤中CD40信号增强

Leukemia
IF13.4
2026-02-190
OA
Treatment-free remission after two nilotinib consolidation durations in chronic myeloid leukemia treated with imatinib: Phase 3 ENESTPath results

伊马替尼治疗慢性粒细胞白血病两次尼洛替尼巩固治疗后的无治疗缓解: 3期ENESTPath结果

Leukemia
IF13.4
2026-01-190
PRE
Differential prognostic impact of myelodysplasia-related gene mutations in a European cohort of 4978 intensively treated AML patients

4978例接受强化治疗的AML欧洲患者队列中,髓系发育异常相关基因突变的不同预后影响

Leukemia
IF13.4
2025-10-270
OA
Real-World Data From a Molecular Tumor Board-Assisted Cancer Care From a Single Center in The Czech Republic: Is Precision Oncology an Accessible Option, or a Privilege for a Minority of Patients?

来自捷克共和国单中心的分子肿瘤委员会辅助癌症治疗的真实世界数据:精准肿瘤学是一种可及的选择,还是少数患者的一种特权?

2025-08-040
OAAI
Gemtuzumab ozogamicin in first-line treatment of CBF-AML: insights from a retrospective multi-center analysis

吉姆单抗奥佐米星在CBF-AML一线治疗中的应用:一项回顾性多中心分析的见解

Leukemia
IF13.4
2025-07-210
OA
2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia

2025欧洲白血病网关于慢性粒细胞白血病治疗的建议

Leukemia
IF13.4
2025-07-110
OA
Endoplasmic reticulum stress disrupts signaling via altered processing of transmembrane receptors

内质网应激通过改变跨膜受体的加工过程来干扰信号传导

2025-04-300
OA
Clinical and Prognostic Significance of Additional Chromosomal Abnormalities at Diagnosis of Chronic Myeloid Leukemia

慢性髓性白血病诊断时额外染色体异常的临床及预后意义

2025-01-280
PRE
Efficacy and Safety Results With Rilzabrutinib, an Oral Bruton Tyrosine Kinase Inhibitor, in Patients With Immune Thrombocytopenia: Phase 2 Part B Study

利扎布鲁替尼(Rilzabrutinib)的疗效和安全性结果:一项在免疫性血小板减少症患者中的口服布鲁顿酪氨酸激酶抑制剂Ⅱ期B部分研究

2025-01-221
OA
Respiratory Viruses in Patients With Hematological Malignancy in Boreal Autumn/Winter 2023-2024: EPICOVIDEHA-EPIFLUEHA Report
2024-12-230
OAAI
Asciminib add-on to imatinib demonstrates sustained high rates of ongoing therapy and deep molecular responses with prolonged follow-up in the ASC4MORE study

Asciminib对伊马替尼的补充在ASC4MORE研究中显示持续的高治疗率和深度分子反应,并延长随访时间

2024-12-180
OAAI
Frequency and Impact of Somatic Mutations Alone or in Combination on Post-Transplant Outcomes in Acute Myeloid Leukemia: A Large Study on Behalf of the EBMT Acute Leukemia Working Party

体细胞突变单独或联合对急性髓系白血病移植后结局的频率和影响:一项由EBMT急性白血病工作组发起的大规模研究

BLOOD
IF23.1
2024-11-050
PRE
Health-related quality of life and symptoms of chronic myeloid leukemia patients after discontinuation of tyrosine kinase inhibitors: results from the EURO-SKI Trial
LEUKEMIA
IF13.4
2024-07-102
PRE
Stromal cells engineered to express T cell factors induce robust CLL cell proliferation in vitro and in PDX co-transplantations allowing the identification of RAF inhibitors as anti-proliferative drugs
LEUKEMIA
IF13.4
2024-06-141
OAAI
Mutations in myeloid transcription factors and activated signaling genes predict chronic myeloid leukemia outcomes
2024-05-171
OAAI